BIOTOSCANA INVESTMENTS S.A.
Corporate Taxpayer’s ID (CNPJ/MF): 19.688.956./0001-56
24, Rue Beck, L 1222, Luxembourg
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

NOTICE TO THE MARKET
REDUCTION OF RELEVANT INTEREST

BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBI033), pursuant to the provisions of CVM Instruction No. 358/2002, as amended, hereby announces to its shareholders and to the market in general that it has received correspondence from GIC Private Limited (“GIC”) on the reduction of equity interest in the Company, and held, on June 26, 2018, 4,391,823 Brazilian Depositary Receipts (“BDRs”) issued by GBT. The shareholding of these investors represents approximately 4.12% of the BDRs issued by GBT.

No additional information on the transaction was received from the said investor.

Montevideo, June 29, 2018

BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal Representative in Brazil

About GBT Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.